<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718117</url>
  </required_header>
  <id_info>
    <org_study_id>A8081060</org_study_id>
    <secondary_id>ALK-2016-CPHG</secondary_id>
    <nct_id>NCT03718117</nct_id>
  </id_info>
  <brief_title>Descriptive Observational Study ALK-2016-CPHG</brief_title>
  <acronym>ALK2016CPHG</acronym>
  <official_title>CHARACTERISTICS OF ADULT PATIENTS TREATED WITH CRIZOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH ALK GENE REARRANGEMENT OR ROS1 GENE REARRANGEMENT IN GENERAL HOSPITALS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French College of General Hospital Pneumologists (CPHG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Descriptive Observational Study.

      Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer
      (NSCLC) Treated With Crizotinib Within General Hospitals
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Describe the characteristics of patients treated with crizotinib Describe efficacy, safety,
      observance and QoL.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 3, 2017</start_date>
  <completion_date type="Anticipated">July 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Demographical Characteristics of Participants</measure>
    <time_frame>Baseline up tp Month 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects using the diagnostic method used to detect ALK (Anaplastic lymphoma kinase) gene rearrangement</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Response through Month 18</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12, Month 15, Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response</measure>
    <time_frame>Baseline up to month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline up to Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a change from baseline in (QLQ-LC 13) Quality of life Questionnaire for Lung Cancer</measure>
    <time_frame>Baseline through Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Morisky self-administered questionnaire</measure>
    <time_frame>Baseline through month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerabitly]</measure>
    <time_frame>Time from first dose of study drug though month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects using diagnostic method used to detect ROS1 gene rearrangement</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline , Month 12, Month 18</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>NSCLC</condition>
  <condition>Crizotinib</condition>
  <condition>ALK Gene Rearrangement or ROS1 Gene Rearrangement</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with ALK positive or ROS1-positive Locally advanced or metastatic non-small
        cell lung cancer NSCLC, initiated in the previous 3 months or participants initiating
        crizotinib treatment regardless of the line of treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age ≥ 18 years

          -  Locally advanced or metastatic NSCLC

          -  Patient ALK gene rearrangement or ROS1 gene rearrangement

          -  Patient having initiated in the previous 3 months or patient initiating crizotinib
             treatment regardless of the line of treatment

          -  Patient followed up by a physician in a hospital pulmonary medicine department

          -  Subject of reproductive age, using an effective method of contraception

          -  Patient informed verbally and in writing on the study and having consented to his/her
             personal data being collected within the scope of the study.

        Non-inclusion criteria

          -  Patient included within the scope of an interventional therapeutic trial

          -  Patient not presenting with ALK gene rearrangement or ROS1 gene rearrangement

          -  Patient not available for follow-up throughout the duration of the study

          -  Patient deemed to be incapable of responding to the study questions for linguistic,
             cognitive or organisational reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal du Pays d'Aix-Pertuis,Service de Pneumologie</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l Europe</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Ballanger, Service de Pneumologie</name>
      <address>
        <city>Aulnay sous Bois</city>
        <zip>93 602</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General Beziers, Service De Pneumologie</name>
      <address>
        <city>Beziers</city>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cannes</name>
      <address>
        <city>Cannes</city>
        <zip>06414</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Chalon sur Saone William Morey</name>
      <address>
        <city>Chalon sur Saone</city>
        <zip>71321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Metropole de Savoie-Site de Chambery</name>
      <address>
        <city>Chambery</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Civils de Colmar - Hopital Louis Pasteur</name>
      <address>
        <city>Colmar Cedex</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier ALPES LEMAN</name>
      <address>
        <city>Contamine sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Frejus</name>
      <address>
        <city>Frejus</city>
        <zip>83600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon Cedex 9</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Vendee</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Mans Hospital Center</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De Libourne - Hopital Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33505</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier des Deux Vallees - Longjumeau BP 125</name>
      <address>
        <city>Longjumeau</city>
        <zip>91161</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Macon</name>
      <address>
        <city>Macon cedex</city>
        <zip>71018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen - Service de Pneumologie</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHR Mulhouse Sud Alsace</name>
      <address>
        <city>Mulhouse</city>
        <zip>68051</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Agglomeration de Nevers</name>
      <address>
        <city>Nevers</city>
        <zip>58033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional d Orleans</name>
      <address>
        <city>Orleans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud Reunion</name>
      <address>
        <city>Saint Pierre La Réunion</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux du Leman</name>
      <address>
        <city>Thonon les Bains</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Troyes, Service de Pneumologie - Oncologie Thoracique</name>
      <address>
        <city>Troyes</city>
        <zip>10003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Villefranche sur Saone - BP80436</name>
      <address>
        <city>Villefranche sur Saone</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A8081060</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer (NSCLC)</keyword>
  <keyword>crizotinib</keyword>
  <keyword>ALK gene rearrangement or ROS1 gene rearrangement</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

